Skip to main content

Advertisement

SpringerLink
Log in

Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting

  • Research Highlights
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

To provide an overview of the key findings from studies in upper gastrointestinal, hepatobiliary, pancreas, and colorectal malignancies presented at ASCO GI 2022.

Methods

We reviewed the abstracts presented at ASCO GI 2022. The studies highlighted were selected by the authors based on their significant discoveries and potential impact on clinical practice.

Results and Conclusion

This year’s hybrid ASCO-GI symposium (2022) introduced many promising new treatment strategies in GI oncology, with several changes in clinical practice for patients with advanced hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic colorectal cancer (CRC).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clinic Oncol. 2022;40(4_suppl):238–238. https://doi.org/10.1200/JCO.2022.40.4_suppl.238.

  2. Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. https://doi.org/10.1016/s0140-6736(21)01234-4.

    Article  CAS  PubMed  Google Scholar 

  3. Metges J-P, Kato K, Sun J-M, et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. J Clinic Oncol. 2022;40(4_suppl):241–241. https://doi.org/10.1200/JCO.2022.40.4_suppl.241.

  4. Shitara K, Janjigian YY, Moehler MH, et al. Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649. J Clin Oncol. 2022;40(4_suppl):240–240. https://doi.org/10.1200/JCO.2022.40.4_suppl.240.

    Article  Google Scholar 

  5. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/s0140-6736(21)00797-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clinic Oncol. 2022;40(4_suppl):379–379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379.

  7. Oh D-Y, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clinic Oncol. 2022;40(4_suppl):378–378. https://doi.org/10.1200/JCO.2022.40.4_suppl.378.

  8. Hammel P, El-Hariry I, Macarulla T, et al. Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441). J Clinic Oncol. 2022;40(4_suppl):518-518. https://doi.org/10.1200/JCO.2022.40.4_suppl.518.

  9. Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. J Clinic Oncol. 2022;40(4_suppl):519–519. https://doi.org/10.1200/JCO.2022.40.4_suppl.519.

  10. Morris VK, Parseghian CM, Escano M, et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J Clinic Oncol. 2022;40(4_suppl):12–12. https://doi.org/10.1200/JCO.2022.40.4_suppl.012.

  11. Lumish MA, Cohen JL, Stadler ZK, et al. PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer. J Clinic Oncol. 2022;40(4_suppl):16–16. https://doi.org/10.1200/JCO.2022.40.4_suppl.016.

  12. Saeed A, Park R, Dai J, et al. Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results. J Clinic Oncol. 2022;40(4_suppl):135–135. https://doi.org/10.1200/JCO.2022.40.4_suppl.135.

  13. Abrams TA, Kazmi SMA, Winer IS, et al. A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort. J Clinic Oncol. 2022;40(4_suppl):121–121. https://doi.org/10.1200/JCO.2022.40.4_suppl.121.

  14. Kotaka M, Shirasu H, Watanabe J, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clinic Oncol. 2022;40(4_suppl):9–9. https://doi.org/10.1200/JCO.2022.40.4_suppl.009.

Download references

Acknowledgements

These abstracts and results were presented during the 2022 ASCO Gastrointestinal Cancers Symposium held in San Francisco, CA from January 20–22, 2022.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, University of California Davis, 2279 45th Street, Sacramento, CA, 95817, USA

    Sepideh Gholami & Mustafa Abidalhassan

  2. Division of Medical Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA

    May Cho

  3. Division of Medical Oncology, Department of Medicine, University of Kansas, Kansas City, KS, USA

    Anwaar Saeed

  4. Division of Surgical Oncology, Department of Surgery, Oregon Health Sciences University, Portland, OR, USA

    Flavio G. Rocha

Authors
  1. Sepideh Gholami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mustafa Abidalhassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. May Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anwaar Saeed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Flavio G. Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FR, MA, MC, AS, and SG jointly concieved and wrote the manuscript.

Corresponding author

Correspondence to Sepideh Gholami.

Ethics declarations

Ethics Approval and Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Conflict of Interest

AS reports research grants (to institution) from AstraZeneca, Bristol Myers Squibb, Merck, Clovis, Exelixis, Actuate Therapeutics, Incyte Corporation, Daiichi Sankyo, Five Prime Therapeutics, Amgen, Innovent Biologics, Dragonfly Therapeutics, KAHR Medical, Biontech, and advisory board fees from AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, and Daiichi Sankyo. FGR reports Consultant-Medtronic, Oncosil; Advisory Board, Astra Zeneca; Research Funding, Gunze. MC reports Speaker’s Bureau for Pfizer, Natera, Taiho, BMS, AstraZeneca, DSI; Advisory Board and Honoraria for Amgen, Incyte, Eisai, Ipsen, Astellas, Taiho, Exelixis, QED, I-Mab, Tempus, Seattle Genetics, HelioDx, Bayer, AstraZeneca, Genentech/Roche, Pfizer, Natera, Taiho, BMS, Basilea. SG report Consulting or Advisory Board for Signatera, QED Therapeutics, TRUSELTIQ; Speakers’ Bureau for Helsinn Therapeutics. MA has no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gholami, S., Abidalhassan, M., Cho, M. et al. Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting. J Gastrointest Canc 54, 672–676 (2023). https://doi.org/10.1007/s12029-022-00849-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-022-00849-5

Keywords

Search

Navigation